Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $42.11, but opened at $46.95. Zealand Pharma A/S shares last traded at $46.95, with a volume of 100 shares.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ZLDPF shares. Berenberg Bank lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. William Blair restated a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. BNP Paribas Exane lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Three investment analysts have rated the stock with a Strong Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, Zealand Pharma A/S currently has an average rating of “Moderate Buy”.

Get Zealand Pharma A/S alerts:

Check Out Our Latest Stock Report on Zealand Pharma A/S

Zealand Pharma A/S Stock Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. The stock’s 50 day moving average is $47.24 and its 200-day moving average is $54.46. The company has a market capitalization of $3.36 billion, a P/E ratio of 3.48 and a beta of 0.88.

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.50. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%.The business had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $2.81 million. As a group, equities research analysts anticipate that Zealand Pharma A/S will post 2.37 earnings per share for the current year.

Zealand Pharma A/S Company Profile

(Get Free Report)

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.

Featured Articles

• Five stocks we like better than Zealand Pharma A/S
• MarketBeat Week in Review – 06/29 – 07/03
• AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
• Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
• Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.